Breast Cancer
Conditions
Keywords
Pyrotinib, Trastuzumab, Pertuzumab
Brief summary
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Detailed description
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.
Interventions
DRUGPyrotinib Plus Trastuzumab
treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
DRUGPertuzumab Plus Trastuzumab
treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive. * Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep 2022. * Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
Exclusion criteria
* Incomplete medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 6 weeks | Progression free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 6 weeks | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
China
Outcome results
None listed